{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T16:24:49Z","timestamp":1792167889256,"version":"4.4.0"},"reference-count":79,"publisher":"Oxford University Press (OUP)","issue":"2","license":[{"start":{"date-parts":[[2026,4,7]],"date-time":"2026-04-07T00:00:00Z","timestamp":1775520000000},"content-version":"vor","delay-in-days":29,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,3,9]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Antibacterial prophylaxis has long been a cornerstone of supportive care in patients with haematological malignancies undergoing intensive chemotherapy and haematopoietic stem cell transplantation (HSCT), particularly in the setting of prolonged and profound neutropenia. However, the widespread use of fluoroquinolone (FQ) prophylaxis has increasingly raised concerns related to antimicrobial resistance, microbiota disruption, drug-related toxicity, and Clostridioides difficile infection, challenging its universal application. At the same time, the therapeutic landscape of haematology is rapidly evolving, with the introduction of novel agents and cellular therapies such as chimeric antigen receptor (CAR) T cells, bispecific antibodies (BsAbs), antibody\u2013drug conjugates, and immune-based treatments, each associated with distinct patterns of immunosuppression and infectious risk. In this narrative review, we critically examine the role of antibacterial prophylaxis through the lens of antimicrobial stewardship, integrating evidence from traditional chemotherapy and transplantation with emerging data from innovative therapies. We summarize current guideline recommendations, real-world evidence, and recent studies questioning the net benefit of routine FQ prophylaxis, particularly in settings with high resistance prevalence. Alternative strategies, including non-FQ agents and selective omission of prophylaxis, are also discussed. Overall, available evidence supports a shift from universal prophylaxis toward a risk-adapted, individualized approach that accounts for treatment modality, expected duration and depth of neutropenia, patient-specific factors, and local epidemiology. Embedding antibacterial prophylaxis decisions within structured antimicrobial stewardship programs is essential to balance infection prevention with long-term patient safety and resistance containment in modern haematological practice.<\/jats:p>","DOI":"10.1093\/jacamr\/dlag051","type":"journal-article","created":{"date-parts":[[2026,3,27]],"date-time":"2026-03-27T12:46:01Z","timestamp":1774615561000},"source":"Crossref","is-referenced-by-count":1,"title":["Antibacterial prophylaxis and antimicrobial stewardship in the era of innovative therapies for haematological malignancies: transplantation, cellular therapies and new drugs"],"prefix":"10.1093","volume":"8","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1058-505X","authenticated-orcid":false,"given":"R","family":"Dell\u2019Acqua","sequence":"first","affiliation":[{"name":"Department of Infectious Diseases, IRCCS Ospedale San Raffaele , Milan 20127 ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M H","family":"Parrinello","sequence":"additional","affiliation":[{"name":"Hematology and Bone Marrow Transplant Unit, IRCCS Ospedale San Raffaele , Via Olgettina 60, Milan 20132 ,","place":["Italy"]},{"name":"Vita-Salute San Raffaele University, IRCCS San Raffaele Scientific Institute , Milan 20132 ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D","family":"Clerici","sequence":"additional","affiliation":[{"name":"Hematology and Bone Marrow Transplant Unit, IRCCS Ospedale San Raffaele , Via Olgettina 60, Milan 20132 ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5124-6970","authenticated-orcid":false,"given":"F","family":"Farina","sequence":"additional","affiliation":[{"name":"Hematology and Bone Marrow Transplant Unit, IRCCS Ospedale San Raffaele , Via Olgettina 60, Milan 20132 ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9656-7217","authenticated-orcid":false,"given":"V","family":"Spagnuolo","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, IRCCS Ospedale San Raffaele , Milan 20127 ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M","family":"Ranzenigo","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, IRCCS Ospedale San Raffaele , Milan 20127 ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M","family":"Negri","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, IRCCS Ospedale San Raffaele , Milan 20127 ,","place":["Italy"]},{"name":"Vita-Salute San Raffaele University, IRCCS San Raffaele Scientific Institute , Milan 20132 ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6117-5328","authenticated-orcid":false,"given":"R","family":"Greco","sequence":"additional","affiliation":[{"name":"Hematology and Bone Marrow Transplant Unit, IRCCS Ospedale San Raffaele , Via Olgettina 60, Milan 20132 ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C","family":"Corti","sequence":"additional","affiliation":[{"name":"Hematology and Bone Marrow Transplant Unit, IRCCS Ospedale San Raffaele , Via Olgettina 60, Milan 20132 ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A","family":"Castagna","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, IRCCS Ospedale San Raffaele , Milan 20127 ,","place":["Italy"]},{"name":"Vita-Salute San Raffaele University, IRCCS San Raffaele Scientific Institute , Milan 20132 ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0873-0123","authenticated-orcid":false,"given":"F","family":"Ciceri","sequence":"additional","affiliation":[{"name":"Hematology and Bone Marrow Transplant Unit, IRCCS Ospedale San Raffaele , Via Olgettina 60, Milan 20132 ,","place":["Italy"]},{"name":"Vita-Salute San Raffaele University, IRCCS San Raffaele Scientific Institute , Milan 20132 ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6380-0377","authenticated-orcid":false,"given":"M","family":"Ripa","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, IRCCS Ospedale San Raffaele , Milan 20127 ,","place":["Italy"]},{"name":"Vita-Salute San Raffaele University, IRCCS San Raffaele Scientific Institute , Milan 20132 ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,4,7]]},"reference":[{"key":"2026040806123792000_dlag051-B1","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1086\/665010","article-title":"Policy statement on antimicrobial stewardship by the Society for Healthcare Epidemiology of America (SHEA), the Infectious Diseases Society of America (IDSA), and the Pediatric Infectious Diseases Society (PIDS)","volume":"33","author":"Fishman","year":"2012","journal-title":"Infect Control Hosp Epidemiol"},{"key":"2026040806123792000_dlag051-B2","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD004386.pub3","article-title":"Antibiotic prophylaxis for bacterial infections in afebrile neutropenic patients following chemotherapy","volume":"1","author":"Gafter-Gvili","year":"2018","journal-title":"Cochrane Database Syst Rev"},{"key":"2026040806123792000_dlag051-B3","doi-asserted-by":"publisher","first-page":"979","DOI":"10.7326\/0003-4819-142-12_part_1-200506210-00008","article-title":"Meta-analysis: antibiotic prophylaxis reduces mortality in neutropenic patients","volume":"142","author":"Gafter-Gvili","year":"2005","journal-title":"Ann Intern Med"},{"key":"2026040806123792000_dlag051-B4","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD004386.pub2","article-title":"Antibiotic prophylaxis for bacterial infections in afebrile neutropenic patients following chemotherapy","volume":"4","author":"Gafter-Gvili","year":"2005","journal-title":"Cochrane Database Syst Rev"},{"key":"2026040806123792000_dlag051-B5","doi-asserted-by":"publisher","first-page":"988","DOI":"10.1056\/NEJMoa050078","article-title":"Antibacterial prophylaxis after chemotherapy for solid tumors and lymphomas","volume":"353","author":"Cullen","year":"2005","journal-title":"N Engl J Med"},{"key":"2026040806123792000_dlag051-B6","doi-asserted-by":"publisher","first-page":"1743","DOI":"10.1002\/cncr.22205","article-title":"Antibiotic prophylaxis in neutropenic patients: new evidence, practical decisions","volume":"107","author":"Leibovici","year":"2006","journal-title":"Cancer"},{"key":"2026040806123792000_dlag051-B7","doi-asserted-by":"publisher","first-page":"977","DOI":"10.1056\/NEJMoa044097","article-title":"Levofloxacin to prevent bacterial infection in patients with cancer and neutropenia","volume":"353","author":"Bucaneve","year":"2005","journal-title":"N Engl J Med"},{"key":"2026040806123792000_dlag051-B8","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1016\/j.ejcsup.2007.06.002","article-title":"Quinolone prophylaxis for bacterial infections in afebrile high risk neutropenic patients","volume":"5","author":"Bucaneve","year":"2007","journal-title":"Eur J Cancer"},{"key":"2026040806123792000_dlag051-B9","doi-asserted-by":"publisher","first-page":"794","DOI":"10.1200\/JCO.2012.45.8661","article-title":"Antimicrobial prophylaxis and outpatient management of fever and neutropenia in adults treated for malignancy: American society of clinical oncology clinical practice guideline","volume":"31","author":"Flowers","year":"2013","journal-title":"J Clin Oncol"},{"key":"2026040806123792000_dlag051-B10","doi-asserted-by":"publisher","first-page":"e56","DOI":"10.1093\/cid\/cir073","article-title":"Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the Infectious Diseases Society of America","volume":"52","author":"Freifeld","year":"2011","journal-title":"Clin Infect Dis"},{"key":"2026040806123792000_dlag051-B11","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1097\/QCO.0000000000001114","article-title":"The role of antibacterial prophylaxis in high-risk neutropenia: benefits, risks, and current perspectives","volume":"38","author":"Douglas","year":"2025","journal-title":"Curr Opin Infect Dis"},{"key":"2026040806123792000_dlag051-B12","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1016\/j.jinf.2017.10.009","article-title":"Fluoroquinolone prophylaxis in haematological cancer patients with neutropenia: ECIL critical appraisal of previous guidelines","volume":"76","author":"Mikulska","year":"2018","journal-title":"J Infect"},{"key":"2026040806123792000_dlag051-B13","doi-asserted-by":"publisher","first-page":"1621","DOI":"10.1182\/bloodadvances.2022008226","article-title":"Levofloxacin prophylaxis vs no prophylaxis in patients with neutropenia within an endemic country for carbapenem-resistant GNB","volume":"7","author":"Clerici","year":"2023","journal-title":"Blood Adv"},{"key":"2026040806123792000_dlag051-B14","doi-asserted-by":"publisher","first-page":"1412","DOI":"10.6004\/jnccn.2012.0146","article-title":"Prevention and treatment of cancer-related infections","volume":"10","author":"Baden","year":"2012","journal-title":"J Natl Compr Canc Netw"},{"key":"2026040806123792000_dlag051-B15","doi-asserted-by":"publisher","first-page":"617","DOI":"10.6004\/jnccn.2024.0056","article-title":"Prevention and treatment of cancer-related infections, version 3.2024","volume":"22","author":"Baden","year":"2024","journal-title":"J Natl Compr Canc Netw"},{"key":"2026040806123792000_dlag051-B16","doi-asserted-by":"publisher","first-page":"1588","DOI":"10.1038\/s41409-020-0811-y","article-title":"Current antimicrobial practice in febrile neutropenia across Europe and Asia: the EBMT infectious disease working party survey","volume":"55","author":"Verlinden","year":"2020","journal-title":"Bone Marrow Transplant"},{"key":"2026040806123792000_dlag051-B17","doi-asserted-by":"publisher","first-page":"v111","DOI":"10.1093\/annonc\/mdw325","article-title":"Management of febrile neutropaenia: ESMO clinical practice guidelines","volume":"27","author":"Klastersky","year":"2016","journal-title":"Ann Oncol"},{"key":"2026040806123792000_dlag051-B18","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2025-993","article-title":"Incidence of infectious complications in acute myeloid leukemia patients undergoing induction chemotherapy with or without fluoroquinolone prophylaxis in real-life: results from INFLUENCER study","volume":"146","author":"Santoni","year":"2025","journal-title":"Blood"},{"key":"2026040806123792000_dlag051-B19","doi-asserted-by":"publisher","first-page":"3043","DOI":"10.1200\/JCO.18.00374","article-title":"JOURNAL OF CLINICAL ONCOLOGY antimicrobial prophylaxis for adult patients with cancer-related immunosuppression: ASCO and IDSA clinical practice guideline update","volume":"36","author":"Taplitz","year":"2018","journal-title":"J Clin Oncol"},{"key":"2026040806123792000_dlag051-B20","doi-asserted-by":"publisher","first-page":"1826","DOI":"10.3324\/haematol.2013.091025","article-title":"European guidelines for empirical antibacterial therapy for febrile neutropenic patients in the era of growing resistance: summary of the 2011 4th European conference on infections in leukemia","volume":"98","author":"Averbuch","year":"2013","journal-title":"Haematologica"},{"key":"2026040806123792000_dlag051-B21","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1038\/bmt.2009.254","article-title":"Guidelines for preventing infectious complications among hematopoietic cell transplant recipients: a global perspective","volume":"44","author":"Tomblyn","year":"2009","journal-title":"Bone Marrow Transplant"},{"key":"2026040806123792000_dlag051-B22","doi-asserted-by":"publisher","first-page":"1884","DOI":"10.1093\/cid\/cix690","article-title":"Incidence, risk factors and outcome of pre-engraftment gram-negative bacteremia after allogeneic and autologous hematopoietic stem cell transplantation: an Italian prospective multicenter survey","volume":"65","author":"Girmenia","year":"2017","journal-title":"Clin Infect Dis"},{"key":"2026040806123792000_dlag051-B23","doi-asserted-by":"publisher","first-page":"1476","DOI":"10.1016\/j.bbmt.2018.02.021","article-title":"Clinical impact of pretransplant multidrug-resistant gram-negative colonization in autologous and allogeneic hematopoietic stem cell transplantation","volume":"24","author":"Forcina","year":"2018","journal-title":"Biol Blood Marrow Transplant"},{"key":"2026040806123792000_dlag051-B24","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1016\/j.bbmt.2016.11.005","article-title":"Risk factors and outcomes of infections by multidrug-resistant gram-negative bacteria in patients undergoing hematopoietic stem cell transplantation","volume":"23","author":"Patriarca","year":"2017","journal-title":"Biol Blood Marrow Transplant"},{"key":"2026040806123792000_dlag051-B25","doi-asserted-by":"publisher","first-page":"1195.e1","DOI":"10.1016\/j.jtct.2024.09.011","article-title":"Antibiotic prophylaxis during allogeneic stem cell transplantation\u2014a comprehensive single center retrospective analysis","volume":"30","author":"Neuerburg","year":"2024","journal-title":"Transplant Cell Ther"},{"key":"2026040806123792000_dlag051-B26","doi-asserted-by":"publisher","first-page":"3289","DOI":"10.1093\/jac\/dkae360","article-title":"Impact of discontinuing routine fluoroquinolone prophylaxis in neutropenic allogeneic haematopoietic stem cell transplant recipients: an observational study","volume":"79","author":"Stern","year":"2024","journal-title":"J Antimicrob Chemother"},{"key":"2026040806123792000_dlag051-B27","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.874117","article-title":"Results of an innovative program for surveillance, prophylaxis, and treatment of infectious complications following allogeneic stem cell transplantation in hematological malignancies (BATMO protocol)","volume":"12","author":"Malagola","year":"2022","journal-title":"Front Oncol"},{"key":"2026040806123792000_dlag051-B28","doi-asserted-by":"publisher","DOI":"10.1093\/jacamr\/dlae010","article-title":"The effect of ciprofloxacin prophylaxis during haematopoietic cell transplantation on infection episodes, exposure to treatment antimicrobials and antimicrobial resistance: a single-centre retrospective cohort study","volume":"6","author":"Baltas","year":"2024","journal-title":"JAC Antimicrob Resist"},{"key":"2026040806123792000_dlag051-B29","doi-asserted-by":"publisher","first-page":"925","DOI":"10.1182\/blood.2019004000","article-title":"How I prevent infections in patients receiving CD19-targeted chimeric antigen receptor T cells for B-cell malignancies","volume":"136","author":"Hill","year":"2020","journal-title":"Blood"},{"key":"2026040806123792000_dlag051-B30","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1182\/blood.2023020578","article-title":"Immune effector cell-associated hematotoxicity: EHA\/EBMT consensus grading and best practice recommendations","volume":"142","author":"Rejeski","year":"2023","journal-title":"Blood"},{"key":"2026040806123792000_dlag051-B31","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1093\/cid\/ciy152","article-title":"Cytokine release syndrome grade as a predictive marker for infections in patients with relapsed or refractory b-cell acute lymphoblastic leukemia treated with chimeric antigen receptor T cells","volume":"67","author":"Park","year":"2018","journal-title":"Clin Infect Dis"},{"key":"2026040806123792000_dlag051-B32","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1182\/blood-2017-07-793760","article-title":"Infectious complications of CD19-targeted chimeric antigen receptor-modified T-cell immunotherapy","volume":"131","author":"Hill","year":"2018","journal-title":"Blood"},{"key":"2026040806123792000_dlag051-B33","doi-asserted-by":"publisher","first-page":"2132","DOI":"10.1038\/s41591-025-03813-5","article-title":"Noncanonical and mortality-defining toxicities of CAR T cell therapy","volume":"31","author":"Rejeski","year":"2025","journal-title":"Nat Med"},{"key":"2026040806123792000_dlag051-B34","doi-asserted-by":"publisher","DOI":"10.1111\/tid.14157","article-title":"Infections after chimeric antigen receptor (CAR)-T-cell therapy for hematologic malignancies","volume":"25","author":"Kampouri","year":"2023","journal-title":"Transpl Infect Dis"},{"key":"2026040806123792000_dlag051-B35","doi-asserted-by":"publisher","first-page":"955","DOI":"10.1016\/j.jtct.2024.07.018","article-title":"Best practice considerations by the American society of transplant and cellular therapy: infection prevention and management after chimeric antigen receptor t cell therapy for hematological malignancies","volume":"30","author":"Shahid","year":"2024","journal-title":"Transplant Cell Ther"},{"key":"2026040806123792000_dlag051-B36","doi-asserted-by":"crossref","DOI":"10.1007\/978-3-030-94353-0","volume-title":"The EBMT\/EHA CAR-T Cell Handbook","author":"Kr\u00f6ger","year":"2022"},{"key":"2026040806123792000_dlag051-B37","doi-asserted-by":"publisher","DOI":"10.1111\/tid.14191","article-title":"Infectious complications among CD19 CAR-T cell therapy recipients: a single-center experience","volume":"25","author":"Walker","year":"2023","journal-title":"Transpl Infect Dis"},{"key":"2026040806123792000_dlag051-B38","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-004475","article-title":"The CAR-HEMATOTOX risk-stratifies patients for severe infections and disease progression after CD19 CAR-T in R\/R LBCL","volume":"10","author":"Rejeski","year":"2022","journal-title":"J Immunother Cancer"},{"key":"2026040806123792000_dlag051-B39","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1566016","article-title":"The impact of antibiotic use on outcomes of relapsed\/refractory multiple myeloma patients treated with CAR-T therapy","volume":"16","author":"Yin","year":"2025","journal-title":"Front Immunol"},{"key":"2026040806123792000_dlag051-B40","doi-asserted-by":"publisher","first-page":"5312","DOI":"10.1182\/bloodadvances.2021004896","article-title":"Infectious complications of CAR T-cell therapy across novel antigen targets in the first 30\u2005days","volume":"5","author":"Mikkilineni","year":"2021","journal-title":"Blood Adv"},{"key":"2026040806123792000_dlag051-B41","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1038\/s41573-024-00896-6","article-title":"The present and future of bispecific antibodies for cancer therapy","volume":"23","author":"Klein","year":"2024","journal-title":"Nat Rev Drug Discov"},{"key":"2026040806123792000_dlag051-B42","doi-asserted-by":"publisher","first-page":"6063","DOI":"10.1182\/bloodadvances.2025016291","article-title":"Comparative infection risk in CAR T vs bispecific antibodies in B-cell lymphoma: a systematic review and meta-analysis","volume":"9","author":"van Besien","year":"2025","journal-title":"Blood Adv"},{"key":"2026040806123792000_dlag051-B43","doi-asserted-by":"publisher","first-page":"764","DOI":"10.1016\/j.cmi.2024.02.023","article-title":"Characteristics and incidence of infections in patients with multiple myeloma treated by bispecific antibodies: a national retrospective study","volume":"30","author":"Jourdes","year":"2024","journal-title":"Clin Microbiol Infect"},{"key":"2026040806123792000_dlag051-B44","doi-asserted-by":"publisher","first-page":"736","DOI":"10.1111\/bjh.18909","article-title":"Recommendations on prevention of infections during chimeric antigen receptor T-cell and bispecific antibody therapy in multiple myeloma","volume":"203","author":"Mohan","year":"2023","journal-title":"Br J Haematol"},{"key":"2026040806123792000_dlag051-B45","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-023-00879-7","article-title":"Monitoring, prophylaxis, and treatment of infections in patients with MM receiving bispecific antibody therapy: consensus recommendations from an expert panel","volume":"13","author":"Raje","year":"2023","journal-title":"Blood Cancer J"},{"key":"2026040806123792000_dlag051-B46","doi-asserted-by":"publisher","first-page":"2259","DOI":"10.1038\/s41591-023-02528-9","article-title":"Elranatamab in relapsed or refractory multiple myeloma: phase 2 MagnetisMM-3 trial results","volume":"29","author":"Lesokhin","year":"2023","journal-title":"Nat Med"},{"key":"2026040806123792000_dlag051-B47","doi-asserted-by":"publisher","first-page":"886","DOI":"10.1002\/cncr.35107","article-title":"Incidence, timing, and management of infections in patients receiving teclistamab for the treatment of relapsed\/refractory multiple myeloma in the MajesTEC-1 study","volume":"130","author":"Nooka","year":"2024","journal-title":"Cancer"},{"key":"2026040806123792000_dlag051-B48","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1016\/j.medcli.2019.07.026","article-title":"Riesgo de infecci\u00f3n asociada a nuevas terapias para el tratamiento de los s\u00edndromes linfoproliferativos","volume":"154","author":"Los-Arcos","year":"2020","journal-title":"Med Cl\u00edn"},{"key":"2026040806123792000_dlag051-B49","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2020-001511","article-title":"Society for immunotherapy of cancer (SITC) clinical practice guideline on immune effector cell-related adverse events","volume":"8","author":"Maus","year":"2020","journal-title":"J Immunother Cancer"},{"key":"2026040806123792000_dlag051-B50","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1080\/14787210.2021.1855143","article-title":"CAR-T cell therapy and infection: a review","volume":"19","author":"Bupha-Intr","year":"2021","journal-title":"Expert Rev Anti Infect Ther"},{"key":"2026040806123792000_dlag051-B51","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1016\/j.annonc.2021.12.003","article-title":"Management of adults and children receiving CAR T-cell therapy: 2021 best practice recommendations of the European society for blood and marrow transplantation (EBMT) and the joint accreditation committee of ISCT and EBMT (JACIE) and the European haematology association (EHA)","volume":"33","author":"Hayden","year":"2022","journal-title":"Ann Oncol"},{"key":"2026040806123792000_dlag051-B52","doi-asserted-by":"publisher","first-page":"e255","DOI":"10.1016\/S1470-2045(23)00159-6","article-title":"Prevention and management of adverse events during treatment with bispecific antibodies and CAR T cells in multiple myeloma: a consensus report of the European myeloma network","volume":"24","author":"Ludwig","year":"2023","journal-title":"Lancet Oncol"},{"key":"2026040806123792000_dlag051-B53","doi-asserted-by":"publisher","first-page":"e205","DOI":"10.1016\/S1470-2045(24)00043-3","article-title":"International myeloma working group immunotherapy committee consensus guidelines and recommendations for optimal use of T-cell-engaging bispecific antibodies in multiple myeloma","volume":"25","author":"Rodriguez-Otero","year":"2024","journal-title":"Lancet Oncol"},{"key":"2026040806123792000_dlag051-B54","doi-asserted-by":"publisher","DOI":"10.1080\/16078454.2024.2448898","article-title":"Risk of infections in bispecific antibody therapy for multiple myeloma: a comprehensive review of literature","volume":"30","author":"Alshammari","year":"2025","journal-title":"Hematology"},{"key":"2026040806123792000_dlag051-B55","doi-asserted-by":"publisher","first-page":"12","DOI":"10.25259\/JHAS_2_2021","article-title":"Monoclonal antibodies used for management of hematological disorders","volume":"1","author":"Ghosh","year":"2021","journal-title":"J Hematol Allied Sci"},{"key":"2026040806123792000_dlag051-B56","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1182\/blood.2024024442","article-title":"Antibody-drug conjugate adverse effects can be understood and addressed based on immune complex clearance mechanisms","volume":"144","author":"Taylor","year":"2024","journal-title":"Blood"},{"key":"2026040806123792000_dlag051-B57","doi-asserted-by":"publisher","DOI":"10.1080\/14740338.2025.2521365","article-title":"Pharmacovigilance insights into antibody\u2013drug conjugates: a multi-database analysis of adverse events in leukemia treatment","author":"Wu","year":"2025","journal-title":"Expert Opin Drug Saf"},{"key":"2026040806123792000_dlag051-B58","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2025-5102","article-title":"First report of the GIMEMA INO-first multicenter observational study analyzing infective and non-infective complications in patients with relapsed or refractory B-cell acute lymphoblastic leukemia treated with inotuzumab ozogamicin","volume":"146","author":"Candoni","year":"2025","journal-title":"Blood"},{"key":"2026040806123792000_dlag051-B59","doi-asserted-by":"publisher","first-page":"909","DOI":"10.1093\/cid\/ciy1025","article-title":"Inflammatory and infectious syndromes associated with cancer immunotherapies","volume":"69","author":"Fishman","year":"2019","journal-title":"Clin Infect Dis"},{"key":"2026040806123792000_dlag051-B60","doi-asserted-by":"publisher","DOI":"10.1186\/s13287-021-02277-x","article-title":"Natural killer cell therapy for hematologic malignancies: successes, challenges, and the future","volume":"12","author":"Lamb","year":"2021","journal-title":"Stem Cell Res Ther"},{"key":"2026040806123792000_dlag051-B61","doi-asserted-by":"publisher","DOI":"10.1016\/j.blre.2023.101073","article-title":"Advances in NK cell therapy for hematologic malignancies: NK source, persistence and tumor targeting","volume":"60","author":"Merino","year":"2023","journal-title":"Blood Rev"},{"key":"2026040806123792000_dlag051-B62","doi-asserted-by":"publisher","DOI":"10.3390\/ijms24010204","article-title":"Leveraging natural killer cell innate immunity against hematologic malignancies: from stem cell transplant to adoptive transfer and beyond","volume":"24","author":"Lin","year":"2023","journal-title":"Int J Mol Sci"},{"key":"2026040806123792000_dlag051-B63","doi-asserted-by":"publisher","first-page":"e143","DOI":"10.1016\/S2352-3026(21)00283-0","article-title":"Consensus guidelines and recommendations for infection prevention in multiple myeloma: a report from the International Myeloma Working Group","volume":"9","author":"Raje","year":"2022","journal-title":"Lancet Haematol"},{"key":"2026040806123792000_dlag051-B64","doi-asserted-by":"publisher","DOI":"10.1016\/j.blre.2025.101287","article-title":"Practical guidance on the prevention and management of infection in multiple myeloma patients: a case-based approach","volume":"72","author":"Kannan","year":"2025","journal-title":"Blood Rev"},{"key":"2026040806123792000_dlag051-B65","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1016\/j.cmi.2024.09.015","article-title":"Prevention and treatment of bacterial infections in patients with haematological cancers and haematopoietic stem cell transplantation: headways and shortcomings","volume":"31","author":"Er","year":"2025","journal-title":"Clin Microbiol Infect"},{"key":"2026040806123792000_dlag051-B66","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1093\/cid\/ciz1082","article-title":"Guideline for antibacterial prophylaxis administration in pediatric cancer and hematopoietic stem cell transplantation","volume":"71","author":"Lehrnbecher","year":"2020","journal-title":"Clin Infect Dis"},{"key":"2026040806123792000_dlag051-B67","doi-asserted-by":"publisher","DOI":"10.1016\/j.jinf.2025.106571","article-title":"Epidemiology of resistant bacterial infections in patients with hematological malignancies or undergoing hematopoietic cell transplantation in Europe: a systematic review by the European conference on infections in leukemia (ECIL)","volume":"91","author":"Baccelli","year":"2025","journal-title":"J Infect"},{"key":"2026040806123792000_dlag051-B68","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000042317","article-title":"Prophylactic fluoroquinolones in hematopoietic stem cell transplant recipients: a meta-analytic comparison of ciprofloxacin and levofloxacin","volume":"104","author":"Albalawi","year":"2025","journal-title":"Medicine"},{"key":"2026040806123792000_dlag051-B69","doi-asserted-by":"publisher","DOI":"10.1111\/ctr.13145","article-title":"Ciprofloxacin vs levofloxacin for prophylaxis during hematopoietic stem-cell transplantation","volume":"32","author":"Copeland","year":"2018","journal-title":"Clin Transplant"},{"key":"2026040806123792000_dlag051-B70","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1093\/jac\/dkx338","article-title":"A comparison of levofloxacin and oral third-generation cephalosporins as antibacterial prophylaxis in acute leukaemia patients during chemotherapy-induced neutropenia","volume":"73","author":"Yemm","year":"2018","journal-title":"J Antimicrob Chemother"},{"key":"2026040806123792000_dlag051-B71","doi-asserted-by":"publisher","first-page":"1637","DOI":"10.1016\/j.bbmt.2019.04.013","article-title":"Levofloxacin versus cefpodoxime for antibacterial prophylaxis in allogeneic stem cell transplantation","volume":"25","author":"Doan","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"key":"2026040806123792000_dlag051-B72","doi-asserted-by":"publisher","first-page":"976","DOI":"10.1016\/j.clinthera.2014.04.013","article-title":"Cefpodoxime for antimicrobial prophylaxis in neutropenia: a retrospective case series","volume":"36","author":"Wojenski","year":"2014","journal-title":"Clin Ther"},{"key":"2026040806123792000_dlag051-B73","doi-asserted-by":"publisher","first-page":"4536","DOI":"10.1002\/cam4.2395","article-title":"Efficacy of antibiotic prophylaxis in patients with cancer and hematopoietic stem cell transplantation recipients: a systematic review of randomized trials","volume":"8","author":"Egan","year":"2019","journal-title":"Cancer Med"},{"key":"2026040806123792000_dlag051-B74","doi-asserted-by":"publisher","first-page":"1632","DOI":"10.1002\/bcp.70051","article-title":"Safety of sulfamethoxazole\u2013trimethoprim for the treatment of bacterial infection in outpatient settings: a systematic review and meta-analysis with active comparator disproportionality analysis","volume":"91","author":"Preyra","year":"2025","journal-title":"Br J Clin Pharmacol"},{"key":"2026040806123792000_dlag051-B75","doi-asserted-by":"publisher","DOI":"10.1111\/tid.14129","article-title":"Antimicrobials in patients with hematologic malignancies and recipients of hematopoietic cell transplantation and other cellular therapies","volume":"25","author":"Tverdek","year":"2023","journal-title":"Transpl Infect Dis"},{"key":"2026040806123792000_dlag051-B76","doi-asserted-by":"publisher","first-page":"1979","DOI":"10.1007\/s00520-017-4040-x","article-title":"Utility of fosfomycin as antibacterial prophylaxis in patients with hematologic malignancies","volume":"26","author":"Zapolskaya","year":"2018","journal-title":"Support Care Cancer"},{"key":"2026040806123792000_dlag051-B77","doi-asserted-by":"publisher","DOI":"10.1186\/s13063-023-07702-5","article-title":"FOVOCIP study: a multicenter randomized trial of fosfomycin versus ciprofloxacin for febrile neutropenia in hematologic patients\u2014efficacy and microbiologic safety","volume":"24","author":"Moreno","year":"2023","journal-title":"Trials"},{"key":"2026040806123792000_dlag051-B78","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1007\/s15010-025-02651-4","article-title":"Infections during AML induction chemotherapy in a contemporary cohort without fluoroquinolone prophylaxis","volume":"54","author":"Ehrlich","year":"2026","journal-title":"Infection"},{"key":"2026040806123792000_dlag051-B79","doi-asserted-by":"publisher","first-page":"1257","DOI":"10.1093\/cid\/ciab404","article-title":"Colonization with fluoroquinolone-resistant enterobacterales decreases the effectiveness of fluoroquinolone prophylaxis in hematopoietic cell transplant recipients","volume":"73","author":"Satlin","year":"2021","journal-title":"Clin Infect Dis"}],"container-title":["JAC-Antimicrobial Resistance"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jacamr\/article-pdf\/8\/2\/dlag051\/67890168\/dlag051.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jacamr\/article-pdf\/8\/2\/dlag051\/67890168\/dlag051.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,8]],"date-time":"2026-04-08T10:12:43Z","timestamp":1775643163000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jacamr\/article\/doi\/10.1093\/jacamr\/dlag051\/8613782"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,9]]},"references-count":79,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,3,9]]}},"URL":"https:\/\/doi.org\/10.1093\/jacamr\/dlag051","relation":{},"ISSN":["2632-1823"],"issn-type":[{"value":"2632-1823","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,4]]},"published":{"date-parts":[[2026,3,9]]},"article-number":"dlag051"}}